< Back

April, 2018

Payers and Providers Facilitate Access to Multiple MS Drugs, Providing Prescribing Options as Needed

Knowledge Edge Brand Access Marketplace Dynamics | April 2018

Payers and Providers Facilitate Access to Multiple MS Drugs, Providing Prescribing Options as Needed

Strong contracting agreements and long market tenure drives better access with both payers and providers for Copaxone 40 mg, Tecfidera, Rebif, Betaseron, Gilenya and Avonex. Newer products and office-administered products lag in line of therapy distinction, as stakeholders typically trial traditional and self-administered drugs initially before moving to those therapies. 

Line of Therapy Assignments by Brand Align Across Payers and Providers

 

 

Download Complimentary Slide

These and other findings can be found in Health Strategies Group’s recently released research Multiple Sclerosis Market Access Stakeholder Drug Management Landscape.

Key topics included in this research:
Summary analysis

  • Capabilities assessment by stakeholder on access risks and opportunities
  • Impact analysis for biopharmaceutical companies

Current stakeholder use of general and brand-specific management tactics

  • Preferred brand selection
  • Utilization management
  • Distribution management
  • Alternative payment models, financial incentives, and performance metrics

View the Research Agenda

Visit our Brand Access Marketplace Dynamics webpage to learn more about this research.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.